[IL-17A and IL-17F: from discovery to target of biologics - an illustrative example of translational research].

Biol Aujourdhui

Département d'immunologie clinique et de rhumatologie, Unité immunogénomique et inflammation, Hôpital Edouard Herriot, Hospices Civils de Lyon, 5 Place d'Arsonval, 69437 Lyon, France.

Published: July 2024

Interleukin (IL)-17A and then IL-17F have been discovered through their roles in chronic inflammatory diseases. These cytokines share 50% of sequence homology and bind to the same receptor made of the IL-17RA et IL-17RC chains. While they have rather similar pro-inflammatory effects, slight differences exist depending on the cell type considered or whether there is TNF or not. Indeed, there is a synergistic effect of TNF and IL-17A or IL-17F on many cell types. In addition, the interactions between immune and stromal cells also modulate their effects which vary according to stromal cell subtype. The identification of IL-17A and IL-17F roles in inflammatory diseases, as psoriasis, has led to the development of inhibitors of those cytokines. Anti-IL-17A, then anti-IL-17A/F and now anti-IL-17RA have been approved for different diseases and are particularly efficient in psoriasis. Their use is expending to other diseases like psoriatic arthritis and spondyloarthritis. Last, the recent understanding of the importance of stromal cells during chronic inflammation explains the relative inefficacy of such inhibitors in some other diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1051/jbio/2024004DOI Listing

Publication Analysis

Top Keywords

il-17a il-17f
12
inflammatory diseases
8
stromal cells
8
diseases
5
[il-17a il-17f
4
il-17f discovery
4
discovery target
4
target biologics
4
biologics illustrative
4
illustrative example
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!